Key points are not available for this paper at this time.
Integrating RNA expression and genome data illuminated treatment options that resulted in 46% of treated patients experiencing positive clinical benefit, supporting the use of comprehensive WGTA profiling in clinical cancer care.
Pleasance et al. (Thu,) studied this question.